Stock Price, News, Quote and Profile of IMMUNITYBIO INC(NASDAQ:IBRX) stock

IMMUNITYBIO INC

NASDAQ:IBRX (12/20/2024, 8:17:44 PM)

After market: 2.6499 +0.03 (+1.14%)

2.62

-0.05 (-1.87%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%36.84%

Sales Q2Q%7346.34%

CRS9.55

6 Month-63.91%

Overview

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Ins Owners5.62%

Inst Owners9.08%

Market Cap1.91B

Shares730.16M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts82.22

Short Float %31.15%

Short Ratio7.12

IPO07-28 2015-07-28

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 672 full-time employees. The company went IPO on 2015-07-28. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.